1373-P: The Prevalence and Risk Factors of Chronic Kidney Disease in Patients with Type 2 Diabetes in China—A Cross-Sectional Study

Abstract

Chronic Kidney Disease (CKD) is a major long-term complication of diabetes and the leading cause of end-stage kidney disease worldwide. It has become very important to regularly screen for early renal disease and rationally use medicines in patients with diabetes and CKD. This was a cross-sectional study, an analysis of baseline data from an ongoing prospective multicenter cohort study, ClinicalTrials.gov ID: NCT05047471. The subjects were outpatients and inpatients from 45 hospitals participating in the endocrinology department from December 2021 to September 2022. Univariate and multivariate binary logistic regression were used to identify risk factors correlated to CKD in patients with type 2 diabetes (T2D). A total of 9886 patients with T2D met our inclusion criteria, please refer to table 1 for the baseline characteristics. The prevalence, screening rate, and awareness rate of CKD was 32.5% [95%CI 31.6, 33.4], 55.3% [95%CI 54.3, 56.3], and 26% [95%CI 24.5, 27.6], respectively. The risk factors independently associated with CKD in patients with T2D were age, duration of T2D, hypertension, LDL-C elevated, poor glycemic control, diabetic foot, diabetic retinopathy, diabetic neuropathy etc., shown in table 2. This work will be helpful in promoting the standardized diagnosis and treatment of CKD in patients with T2D in China, and in arousing the attention of patients with T2D to CKD. Disclosure D.Zhu: None. Y.Mu: Speaker's Bureau; Abbott Diabetes, Boehringer Ingelheim Inc., Novo Nordisk (China), Sanifit. L.Shi: None. Y.Xue: None. X.Yu: None. Y.Wang: None. T.Hong: Speaker's Bureau; Novo Nordisk (China), Sanofi China, Eli Lilly and Company, Merck Sharp & Dohme Corp., Merck & Co., Inc., Boehringer Ingelheim Inc., AstraZeneca, Bayer Inc. X.Li: None. J.Ma: None. Funding Beijing Great Physician Commonwealth Foundation (DYJ20210621)